カテゴリ： GlobalData, イギリス, 企業調査

Hikma Pharmaceuticals Plc (HIK)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Hikma Pharmaceuticals Plc (HIK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10020
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：72
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and Rest of the World (ROW). Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc (HIK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 16
Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 17
Venture Financing 18
Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18
Prognos Health Raises USD20.5 Million in Series C Financing 20
Partnerships 21
Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 21
Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 22
Hikma Pharma Forms Joint Venture With Midroc Pharma 23
Venture Life Enters into Distribution Agreement with Hikma Pharma 24
Licensing Agreements 25
Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 25
Hikma Pharma Enters into Licensing Agreement with Rovi 26
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 27
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 28
Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 29
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 30
Hikma Pharma Enters into Licensing Agreement with Octapharma 31
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 32
Hikma Pharma Enters into Licensing Agreement with Vitabiotics 33
Hikma Pharma Enters into Licensing Agreement with Azanta 34
Hikma Pharma Enters into Licensing Agreement with SK Chemicals 35
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 36
Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 37
Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 38
Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 39
Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 40
Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 41
Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 42
Debt Offering 43
Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43
Asset Transactions 44
Amphastar Pharma Acquires 14 ANDAs from Hikma Pharma for USD4 Million 44
Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 45
Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 46
Acquisition 47
Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 47
Hikma Pharma to Acquire EIMC United Pharma 49
Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 50
Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 52
Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 53
Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For US$42 Million 54
Hikma Pharmaceuticals Plc – Key Competitors 55
Hikma Pharmaceuticals Plc – Key Employees 56
Hikma Pharmaceuticals Plc – Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Joint Venture 58
Recent Developments 59
Financial Announcements 59
Aug 15, 2018: Hikma Pharmaceuticals: Half-year report 59
Mar 14, 2018: Hikma reports 2017 full year results 64
Aug 17, 2017: Hikma Delivers Stable Profitability and Strong Cash Generation In H1 and Maintains a Solid Balance Sheet 65
Mar 15, 2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency 66
Corporate Communications 67
Jun 04, 2018: Hikma Appoints Henriette Nielsen As Chief Transformation Officer 67
Feb 20, 2018: Sigurdur Olafsson appointed Chief Executive Officer of Hikma 68
Jan 15, 2018: Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific Officer and Global Head of R&D 69
Jun 26, 2017: Hikma Pharmaceuticals Announces Leadership and Organisational Changes to US Business 70
Other Significant Developments 71
May 03, 2017: Hikma Changes Registered Office 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hikma Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 16
Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 17
Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18
Prognos Health Raises USD20.5 Million in Series C Financing 20
Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 21
Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 22
Hikma Pharma Forms Joint Venture With Midroc Pharma 23
Venture Life Enters into Distribution Agreement with Hikma Pharma 24
Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 25
Hikma Pharma Enters into Licensing Agreement with Rovi 26
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 27
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 28
Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 29
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 30
Hikma Pharma Enters into Licensing Agreement with Octapharma 31
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 32
Hikma Pharma Enters into Licensing Agreement with Vitabiotics 33
Hikma Pharma Enters into Licensing Agreement with Azanta 34
Hikma Pharma Enters into Licensing Agreement with SK Chemicals 35
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 36
Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 37
Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 38
Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 39
Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 40
Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 41
Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 42
Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43
Amphastar Pharma Acquires 14 ANDAs from Hikma Pharma for USD4 Million 44
Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 45
Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 46
Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 47
Hikma Pharma to Acquire EIMC United Pharma 49
Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 50
Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 52
Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 53
Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For US$42 Million 54
Hikma Pharmaceuticals Plc, Key Competitors 55
Hikma Pharmaceuticals Plc, Key Employees 56
Hikma Pharmaceuticals Plc, Subsidiaries 57
Hikma Pharmaceuticals Plc, Joint Venture 58

List of Figures
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Hikma Pharmaceuticals Plc (HIK)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • TBG Diagnostics Ltd (TDL)：医療機器：M&Aディール及び事業提携情報
    Summary TBG Diagnostics Ltd (TBG Diagnostics), formerly Progen Pharmaceuticals Ltd, is a molecular diagnostics company that develops, manufactures and markets molecular diagnostics kits, instruments and services. The company’s major products include nucleic acid extraction kits, HLA SBT typing kits, …
  • The National Gas Company of Trinidad and Tobago Ltd：企業の戦略的SWOT分析
    The National Gas Company of Trinidad and Tobago Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key compe …
  • Ayala Corporation (AC)-エネルギー分野：企業M&A・提携分析
    Summary Ayala Corporation (Ayala) is a business conglomerate with diversified business groups. It operates in real estate, financial services, water, telecommunications, automotive, power generation, transport infrastructure, electronics manufacturing services, business process outsourcing, educatio …
  • Invectys SA：製薬・医療：M&Aディール及び事業提携情報
    Summary Invectys SA (Invectys) is a biopharmaceutical company that develops immunotherapy to treat cancer. The company provides product pipeline such as INVAC-1, a DNA vaccine targeting Telomerase; Universal Cancer Peptide vaccine UCPVax. It offers products such as a human telomerase peptide-based v …
  • Probiogen AG：企業のM&A・事業提携・投資動向
    Probiogen AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Probiogen AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Ethan Allen Interiors Inc. (ETH)：企業の財務・戦略的SWOT分析
    Ethan Allen Interiors Inc. (ETH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Eni SpA (ENI)-エネルギー分野：企業M&A・提携分析
    Summary Eni S.p.A. (Eni) is an integrated oil and gas company, which carries out oil and natural gas exploration, field development and production activities. It also involves in supply, trading and shipping of natural gas, LNG, electricity and fuels. The company manages developed and undeveloped ac …
  • Tokyo Electron Limited：企業の戦略・SWOT・財務情報
    Tokyo Electron Limited - Strategy, SWOT and Corporate Finance Report Summary Tokyo Electron Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Noble Corporation Plc (NE)：石油・ガス：M&Aディール及び事業提携情報
    Summary Noble Corporation Plc (Noble) is an offshore drilling contractor for the oil and gas industry. It provides contract drilling services with its fleet of mobile offshore drilling units. The company’s offshore rig fleet operates in the global market and provides contract drilling services. Nobl …
  • Xactware Solutions Inc：企業の戦略的SWOT分析
    Xactware Solutions Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Hornbeck Offshore Services, Inc. (HOS)-石油・ガス分野：企業M&A・提携分析
    Summary Hornbeck Offshore Services, Inc. (HOS) is a provider of marine services. The company offers marine transportation, subsea installation and accommodation support services to exploration and production, oilfield service, offshore construction and the US military customers. It supplies vessels, …
  • Bank of Singapore Ltd.：企業の戦略・SWOT・財務情報
    Bank of Singapore Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of Singapore Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Smith & Nephew Plc (SN.)：医療機器：M&Aディール及び事業提携情報
    Summary Smith & Nephew Plc (Smith & Nephew) is a medical technology company that develops, manufactures and markets medical devices for use in orthopaedic reconstruction and trauma, sports medicines and advanced wound management. The company offers its products in various categories including Sports …
  • ANI Pharmaceuticals Inc (ANIP)：製薬・医療：M&Aディール及び事業提携情報
    Summary ANI Pharmaceuticals Inc (ANI) formerly BioSante Pharmaceuticals Inc, is a specialty pharmaceutical company that develops, manufactures and markets pharmaceuticals. The company’s product portfolio encompasses generic and branded tablets indicated for ulcerative colitis; osteoarthritis; rheuma …
  • Petoro AS：企業の戦略的SWOT分析
    Petoro AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Bank Sepah：企業の戦略・SWOT・財務情報
    Bank Sepah - Strategy, SWOT and Corporate Finance Report Summary Bank Sepah - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Bill & Melinda Gates Foundation-製薬・医療分野：企業M&A・提携分析
    Summary Bill & Melinda Gates Foundation (BMGF), formerly William H. Gates Foundation is a provider of health development programs. The foundation concentrates on improving healthcare, decrease poverty in America and provides access to information equipment. It offers global health services in the fi …
  • Lockheed Martin Corporation：戦略・SWOT・企業財務分析
    Lockheed Martin Corporation - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Koninklijke Ten Cate NV：企業の戦略的SWOT分析
    Koninklijke Ten Cate NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Exide Technologies：企業の戦略的SWOT分析
    Exide Technologies - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆